Mediolanum International Funds Ltd Acquires 25,786 Shares of Insulet Corporation $PODD

Mediolanum International Funds Ltd increased its holdings in Insulet Corporation (NASDAQ:PODD) by 121.3% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 47,050 shares of the medical instruments supplier’s stock after purchasing an additional 25,786 shares during the period. Mediolanum International Funds Ltd’s holdings in Insulet were worth $14,730,000 as of its most recent filing with the SEC.

Other hedge funds have also added to or reduced their stakes in the company. Zions Bancorporation National Association UT bought a new position in Insulet in the first quarter valued at about $26,000. SouthState Corp raised its holdings in Insulet by 253.3% in the 1st quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock worth $28,000 after purchasing an additional 76 shares during the period. Kozak & Associates Inc. bought a new stake in Insulet during the second quarter valued at about $32,000. Golden State Wealth Management LLC increased its position in Insulet by 202.9% in the second quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock worth $32,000 after buying an additional 69 shares in the last quarter. Finally, Trust Co. of Toledo NA OH bought a new position in shares of Insulet in the second quarter worth about $35,000.

Insider Activity

In related news, SVP Prem Singh sold 687 shares of the stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the transaction, the senior vice president owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the sale, the senior vice president directly owned 3,890 shares in the company, valued at $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.39% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

PODD has been the subject of several analyst reports. Stifel Nicolaus assumed coverage on shares of Insulet in a report on Tuesday, October 21st. They issued a “buy” rating and a $370.00 target price for the company. Wall Street Zen upgraded shares of Insulet from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Morgan Stanley reissued an “overweight” rating on shares of Insulet in a report on Thursday, August 7th. Barclays upped their price objective on Insulet from $300.00 to $301.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 5th. Finally, Leerink Partners boosted their price target on Insulet from $385.00 to $386.00 and gave the stock an “outperform” rating in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $379.45.

Insulet Stock Performance

NASDAQ PODD opened at $331.17 on Friday. The stock has a market capitalization of $23.30 billion, a PE ratio of 100.66, a P/E/G ratio of 2.64 and a beta of 1.39. Insulet Corporation has a 1-year low of $230.05 and a 1-year high of $354.88. The business has a 50 day simple moving average of $322.22 and a two-hundred day simple moving average of $314.69. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, beating analysts’ consensus estimates of $1.13 by $0.11. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The firm had revenue of $521.70 million during the quarter, compared to the consensus estimate of $678.70 million. During the same period in the prior year, the company earned $1.08 EPS. The company’s quarterly revenue was up 29.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, research analysts predict that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.